May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Role of NF-B and Bortezomib in Uveal Melanoma
Author Affiliations & Notes
  • K. D. Godeiro
    Ophthalmology, Federal University of Sao Paulo / UNIFESP-EPM, Sao Paulo, Brazil
  • E. Antecka
    Ophthalmology, McGill University, Montreal, Quebec, Canada
  • J. C. Marshal
    Ophthalmology, McGill University, Montreal, Quebec, Canada
  • S. Maloney
    Ophthalmology, McGill University, Montreal, Quebec, Canada
  • M. N. Burnier, Jr.
    Ophthalmology, McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  K.D. Godeiro, None; E. Antecka, None; J.C. Marshal, None; S. Maloney, None; M.N. Burnier, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 64. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. D. Godeiro, E. Antecka, J. C. Marshal, S. Maloney, M. N. Burnier, Jr.; The Role of NF-B and Bortezomib in Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):64. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Uveal melanoma (UM) is the most common primary intra-ocular malignancy in adults. Despite the high accuracy of clinical diagnosis and advances in local treatment, more than 40% of UM patients will develop metastases that ultimately lead to death. It has been previously shown by our laboratory that the nuclear factor-kappa B (NF-ΚB), a transcription factor related to carcinogenesis, is highly expressed in UM specimens . Bortezomib is a NF-ΚB inhibitor, which received accelerated FDA approval to treat multiple myeloma patients refractory to previous therapies. Although the role of NF-ΚB in protecting skin melanoma cells from apoptosis and the effects of bortezomib in skin melanoma have received considerable interest recently, the role of NF-ΚB and bortezomib in UM has not yet been studied.

Methods: : Four human UM cell lines and one human transformed uveal melanocyte cell line were assayed for proliferative ability under conditions of increasing concentrations of bortezomib.

Results: : All UM cell lines exposed to bortezomib disclosed a very statistically significant decreased proliferation rate when compared to the control group.

Conclusions: : The results of this study demonstrated that NF-ΚB is highly expressed in UM and that bortezomib treatment effectively decreases the proliferation rate of human UM cell lines. Recent advances in the development of drugs that down-regulate NF-ΚB signalling may therefore provide potential adjuvant modalities to conventional therapies in UM.

Keywords: melanoma • uvea • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×